Journal of Antimicrobial Chemotherapy (1999) 43, 846-848
© 1999 The British Society for Antimicrobial Chemotherapy
Correspondence |
Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area
J Antimicrob Chemother 1999; 43: 846–848
a Institut für Medizinische Mikrobiologie und Virologie, Universität Düsseldorf, Universitätsstrasse 1, Geb. 22.21, D-40225 Düsseldorf, Germany; b Eijkman-Winkler Institute for Medical Microbiology, University Hospital Utrecht, Utrecht, The Netherlands; c Chirurgische Klinik des Gerresheimer Krankenhauses Düsseldorf, Düsseldorf; d Bayer AG, PH-Research Antiinfectives, Wuppertal; e Robert Koch Institut, Nationales Referenzzentrum für Staphylokokken, Bereich Wernigerode, Germany
Sir,
Hiramatsu et al.
1,2,3 recently described the emergence in Japanese
hospitals of heterogeneous intermediate resistance to vancomycin in clinical isolates of Staphylococcus aureus (hetero-VISA, also referred to as `hetero-VRSA' ).
(A
hetero-VISA strain is one that is susceptible to vancomycin, i.e. MIC 
4 mg/L, according to
breakpoints recommended by the National Committee for Clinical Laboratory Standards
(NCCLS),
4 but which contains subpopulations of cells, at frequencies
10
- 6,
1 that exhibit intermediate susceptibility, i.e. MICs 8- 16
mg/L.)
These investigators reported the incidences of such isolates to be 20% in Juntendo University
Hospital,
9.3% in seven other university hospitals and 1.3% in non-university hospitals.
1,2 All of the strains
possessed the same pulsed-field gel electrophoresis (PFGE) pattern, II-A— an
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Gazzola and P. S. Cocconcelli Vancomycin heteroresistance and biofilm formation in Staphylococcus epidermidis from food Microbiology, October 1, 2008; 154(10): 3224 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Domenech, S. Ribes, C. Cabellos, F. Taberner, F. Tubau, M. A. Dominguez, A. Montero, J. Linares, J. Ariza, and F. Gudiol Experimental study on the efficacy of combinations of glycopeptides and {beta}-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides J. Antimicrob. Chemother., October 1, 2005; 56(4): 709 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sancak, S. Ercis, D. Menemenlioglu, S. Colakoglu, and G. Hascelik Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital J. Antimicrob. Chemother., September 1, 2005; 56(3): 519 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liu and H. F. Chambers Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3040 - 3045. [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Kim, W. B. Park, K. D. Lee, Y. J. Choi, S. W. Park, M.-d. Oh, E.-C. Kim, and K. W. Choe Nationwide Surveillance for Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Korea J. Clin. Microbiol., June 1, 2003; 41(6): 2279 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Van Griethuysen, A. Van 't Veen, A. Buiting, T. Walsh, and J. Kluytmans High Percentage of Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Glycopeptides in The Netherlands J. Clin. Microbiol., June 1, 2003; 41(6): 2487 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Decousser, P. Pina, F. Picot, C. Delalande, B. Pangon, P. Courvalin, P. Allouch, and the ColBVH study group Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey J. Antimicrob. Chemother., May 1, 2003; 51(5): 1213 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill, I. Chopra, G. Bierbaum, A. Reipert, and F. Schaaff Lack of Evidence for Involvement of Hypermutability in Emergence of Vancomycin-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1484 - 1485. [Full Text] [PDF]
|
|
|
|
|
|
A. Reipert, K. Ehlert, T. Kast, and G. Bierbaum Morphological and Genetic Differences in Two Isogenic Staphylococcus aureus Strains with Decreased Susceptibilities to Vancomycin Antimicrob. Agents Chemother., February 1, 2003; 47(2): 568 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Schaaff, A. Reipert, and G. Bierbaum An Elevated Mutation Frequency Favors Development of Vancomycin Resistance in Staphylococcus aureus Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3540 - 3548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. MacKenzie, P. Greig, D. Morrison, G. Edwards, and I. M. Gould Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland J. Antimicrob. Chemother., November 1, 2002; 50(5): 689 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Denis, C. Nonhoff, B. Byl, C. Knoop, S. Bobin-Dubreux, and M. J. Struelens Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features J. Antimicrob. Chemother., September 1, 2002; 50(3): 383 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, M. Boos, S. Mayer, H. Jagusch, and A. C. Fluit Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother., February 1, 2002; 49(2): 283 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Boyle-Vavra, R. B. Carey, and R. S. Daum Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate J. Antimicrob. Chemother., November 1, 2001; 48(5): 617 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Fluit, C. L. C. Wielders, J. Verhoef, and F.-J. Schmitz Epidemiology and Susceptibility of 3,051 Staphylococcus aureus Isolates from 25 University Hospitals Participating in the European SENTRY Study J. Clin. Microbiol., October 1, 2001; 39(10): 3727 - 3732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Walsh, A. Bolmstrom, A. Qwarnstrom, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides J. Clin. Microbiol., July 1, 2001; 39(7): 2439 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wootton, R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital J. Antimicrob. Chemother., April 1, 2001; 47(4): 399 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Trakulsomboon, S. Danchaivijitr, Y. Rongrungruang, C. Dhiraputra, W. Susaemgrat, T. Ito, and K. Hiramatsu First Report of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Thailand J. Clin. Microbiol., February 1, 2001; 39(2): 591 - 595. [Abstract] [Full Text]
|
|
|
|
|
|
S. Boyle-Vavra, H. Labischinski, C. C. Ebert, K. Ehlert, and R. S. Daum A Spectrum of Changes Occurs in Peptidoglycan Composition of Glycopeptide-Intermediate Clinical Staphylococcus aureus Isolates Antimicrob. Agents Chemother., January 1, 2001; 45(1): 280 - 287. [Abstract] [Full Text]
|
|
|
|
|
|
R. H. Drew, J. R. Perfect, L. Srinath, E. Kurkimilis, M. Dowzicky, G. H. Talbot, and for the Synercid Emergency-Use Study Group Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy J. Antimicrob. Chemother., November 1, 2000; 46(5): 775 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, A. C. Fluit, D. Milatovic, J. Verhoef, H.-P. Heinz, and S. Brisse In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother., July 1, 2000; 46(1): 109 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Chesneau, A. Morvan, and N. E. Solh Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals J. Antimicrob. Chemother., June 1, 2000; 45(6): 887 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Woodford, M. Warner, and H. M. Aucken Vancomycin resistance among epidemic strains of methicillin-resistant Staphylococcus aureus in England and Wales J. Antimicrob. Chemother., February 1, 2000; 45(2): 258 - 259. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Howe, M. Wootton, T. R. Walsh, P. M. Bennett, and A. P. Macgowan Heterogeneous resistance to vancomycin in Staphylococcus aureus J. Antimicrob. Chemother., January 1, 2000; 45(1): 130 - 131. [Full Text] [PDF]
|
|
|
|
|
|
R. Geisel, F.-J. Schmitz, L. Thomas, H. Labischinsky, and W. Witte Reply J. Antimicrob. Chemother., January 1, 2000; 45(1): 131 - 132. [Full Text] [PDF]
|
|